Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
MannKind presented new clinical and real-world data for Afrezza at the ADA 2026 Scientific Sessions, reinforcing the product's safety and efficacy following its recent pediatric label expansion. Post-hoc analyses from the INHALE-1 study showed that pediatric patients treated with inhaled insulin reported greater treatment satisfaction than those on rapid-acting analogs, while achieving similar glycemic control.
Key figures
- Drug Name
- Afrezza
- Lispro onset
- 10% within 60 minutes
- Ada meeting dates
- June 5-8, 2026
- Inhaled insulin onset
- >50% within 60 minutes
- Pediatric approval date
- May 29, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.